Skip to main content
Karo Pharma AB logo

Karo Pharma AB — Investor Relations & Filings

Ticker · KARO ISIN · SE0007464888 LEI · 213800G54Z51LOPGTA79 ST Manufacturing
Open in API
Filings indexed 653 across all filing types
Latest filing 2019-04-09 Annual Report
Country SE Sweden
Listing ST KARO

About Karo Pharma AB

https://www.karohealthcare.com/

Karo Pharma AB, operating as Karo Healthcare, is a healthcare company that develops, markets, and sells a broad portfolio of everyday healthcare products. The company's offerings are designed to prevent illness and treat common health problems, empowering consumers to manage their daily well-being. The portfolio consists of various branded medicines and consumer healthcare products distributed through pharmacies and directly to healthcare providers. With products available in over 90 countries, the company focuses on becoming a leading force in its sector by employing a consumer-centric approach, strategic innovation, and omnichannel excellence.

Recent filings

Filing Released Lang Actions
Annual Report 2018
Annual Report Classification · 100% confidence The document is titled 'Årsredovisning 2018' (Annual Report 2018) for Karo Pharma AB. It contains comprehensive financial statements, a management report (Förvaltningsberättelse), notes, a five-year summary, and an auditor's report. It is clearly the full annual report for the fiscal year 2018, not an announcement or a summary. FY 2018
2019-04-09 Swedish
Ändrat datum för Karo Pharmas årsstämma
Report Publication Announcement Classification · 99% confidence The document is a short announcement (1002 characters) in Swedish regarding the Annual General Meeting (Årsstämma) of Karo Pharma. The key information is the change in the date for the AGM, moving it to May 16, 2019. This directly relates to the Annual General Meeting. Although it is an announcement about the meeting, the specific category for AGM materials/information is 'AGM-R'. Since this is a direct announcement about the meeting logistics rather than a general regulatory filing (RNS) or a proxy statement (PSI), AGM-R is the most appropriate fit, as it covers materials shared during or related to the AGM.
2019-04-09 Swedish
New date for the annual general meeting of Karo Pharma
AGM Information Classification · 98% confidence The document explicitly announces a 'NEW DATE FOR THE ANNUAL GENERAL MEETING OF KARO PHARMA' and specifies the rescheduled date (16 May 2019). This content directly relates to the scheduling and logistics of the Annual General Meeting (AGM). Therefore, the most appropriate classification is AGM Information (AGM-R). The document length is short (1098 chars), but the content is the announcement itself, not a report, making AGM-R more specific than RPA or RNS.
2019-04-09 English
Christoffer Lorenzen appointed CEO of Karo Pharma; Peter Blom resigning.
Board/Management Information Classification · 99% confidence The document is a press release announcing a change in senior management: the appointment of a new CEO (Christoffer Lorenzen) and the resignation of the previous CEO (Peter Blom). This directly aligns with the definition of 'Board/Management Information' (MANG). The text details the transition, effective dates, and background of the incoming executive. It is not a financial report (10-K, IR, ER), a shareholder vote result (DVA), or a general regulatory filing (RNS), but a specific announcement about management personnel.
2019-04-03 English
Christoffer Lorenzen utsedd till VD för Karo Pharma; Peter Blom avgår.
Board/Management Information Classification · 99% confidence The document text is a press release announcing a change in senior management: Christoffer Lorenzen is appointed as the new CEO, replacing Peter Blom, with Ulf Mattsson serving as interim CEO until July 1, 2019. This content directly matches the definition for Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management. The document is short and appears to be an official announcement, not a comprehensive report.
2019-04-03 Swedish
BESLUT VID KARO PHARMAS EXTRA BOLAGSSTÄMMA DEN 14 FEBRUARI 2019
AGM Information Classification · 99% confidence The document is titled "BESLUT VID KARO PHARMAS EXTRA BOLAGSSTÄMMA DEN 14 FEBRUARI 2019" (Decisions at Karo Pharma's Extraordinary General Meeting on February 14, 2019). It details specific resolutions passed regarding the composition of the Board of Directors (styrelse) and board remuneration (styrelsearvoden). This content directly relates to decisions made at a shareholder meeting, specifically an Extraordinary General Meeting (EGM), which falls under the scope of AGM/EGM related materials. Since the document explicitly details the *results* of the voting on board composition and remuneration, it is best classified as related to AGM information, although it is not the formal voting result declaration (DVA). Given the options, AGM-R (AGM Information) is the most appropriate fit for decisions made at a General Meeting, as opposed to a general regulatory filing (RNS) or a specific remuneration report (DEF 14A). The document is short and appears to be a press release summarizing the meeting outcomes.
2019-02-14 Swedish

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.